Single dose of esketamine during surgery may ward off Post-Op depression in ovarian cancer patients

NCT ID NCT06624878

Completed Prevention Sponsor: Zhejiang Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving a low dose of esketamine during ovarian cancer surgery could prevent depressive symptoms that often follow. 568 women undergoing cytoreductive surgery received either esketamine or a placebo. Researchers measured depression using a standard questionnaire three days after surgery. The goal is to find a simple way to protect mental health during a difficult treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: esketamine
What this could lead to: If it works, this could offer a simple way to prevent depression after major cancer surgery, improving mental health and recovery.
What could go wrong: This is a single completed trial with a specific dose and timing. Results may not apply to other surgeries or populations, and the effect may be small or not lasting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOREDUCTIVE SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOREDUCTIVE SURGERY DEPRESSIVE SYMPTOM OVARIAN CANCER

Contacts and locations

Locations

Zhejiang cancer hospital

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.